Nonsteroidal anti-inflammatory therapy effectively prevents the development of proliferative vitreoretinopathy in the experiment

Introduction and purpose. Proliferative vitreoretinopathy (PVR) is caused by retinal damage and increased permeability of the blood-ocular barrier. Activation of inflammation, cell migration and proliferation leading to the membrane formation on the surface of the retina in the lesion area, causes blindness. After surgical removal of all membranes the frequency of PVR recurrence is 30 % on average. Therapeutic approaches are not developed. Since inflammation plays a key role in PVR formation, the aim of our study was to justify the use of non-steroidal anti-inflammatory drug lornoxicam for prevention of the development of proliferative vitreoretinopathy. Materials and methods. The work was performed on rats. PVR was modeled by intravitreal injection of dispase, 0,015 U/μl. Intravitreal administration of lornoxicam was performed 20 minutes later, 8 mg/ml. Volume of injections was 2 μl. On the second and the third day of the experiment we performed intraperitoneal injections of the drug in a dose of 230 mg/kg. Intact animals were used as a control group. Enucleation of the eyes was performed on the first, third, seventh and 42th day of the experiment. Results. Lornoxicam reduced the inflammatory response caused by the dispase introduction. It shifted the start of retinal remodeling from the first to the third day of the experiment, restrained a formation of «rosette» structures in the retina (p<0.05), decreased the rate of destruction of photoreceptors by 34 % (p<0.05) and caused twofold decrease (p<0.05) in the severity of photoreceptor changes. Throughout the experiment, the thickness of retinal and choroidal layers among the treated animals was the same as the thickness of retina and choroid of intact rats. The dispase introduction was accompanied by fibrous membrane formation during the period from 7th to 42th day after the beginning of the experiment. Lornoxicam decreased the incidence of membrane formation by 43 % (p<0.05), and the membranes were smaller and contained less fibrotic components. Conclusions. The use of lornoxicam during early period of PVR development reduced the manifestation of signs of inflammation in the eye: it controlled retinal remodeling at all stages of the disease, decreased the incidences of membrane formation by 43 % and significantly reduced the intensity of fibrotic processes in the membranes.

лорноксикам, пролиферативная витреоретинопатия, НПВС, мембрана, ремоделирование сетчатки, lornoxicam, proliferative vitreoretinopathy, NSAIDs, membrane, retinal remodeling

1. Гаврилова С. А., Липина Т. В., Загидулин Т. Р. и др. Протекторное действие лорноксикама на развитие инфаркта миокарда у крыс в условиях ишемии и ишемии-реперфузии // Кардиология. 2008. Т. 48. № 12. С. 42-48.

2. Ердяков А. К., Тихонович М. В., Ржавина Е. М. и др. Характеристика сетчатки при развитии пролиферативной витреоретинопатии у крыс после внутриглазной инъекции конканавалина А и диспазы // Росс. физиолог. журн им. И. М. Сеченова. 2015. Т. 101. № 5. С. 572-585.

3. Тихонович М. В., Гаврилова С. А., Таратин Д. В. и др. Ингибирование циклооксигеназ уменьшает размер некроза и гибель нейронов в коре головного мозга крыс с ишемическим инсультом и инсультом, осложненным реперфузией сонных артерий // Регионарное кровообращение и микроциркуляция. 2012. Т. 11. № 4 (44). С. 83-90.

4. Тихонович М. В., Гаврилова С. А. Способ моделирования пролиферативной витреоретинопатии у крыс: патент РФ № 2558991 // Бюл. 2015. № 22. 7 с.

5. Тихонович М. В., Лыскин П. В., Иойлева Е. Э. и др. Экспрессия ростовых, трофических и провоспалительных факторов в эпиретинальных мембранах пациентов с тяжелой формой пролиферативной витреоретинопатии // Офтальмохирургия. 2015. Т. 4. С. 36-42.

6. Тихонович М. В., Иойлева Е. Э., Гаврилова С. А. Роль воспаления в развитии пролиферативной витреоретинопатии // Клин. мед. 2015. Т. 93. № 7. С. 14-20.

7. Diakonis V. F, Tsourdou A., Tzatzarakis M. N. et al. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo) // J. Ocul. Pharmacol. Ther. 2013. Vol. 29. № 7. P. 627-632.

8. Delyfer M.-N., Raffelsberger W., Mercier D. et al. Transcriptomic analysis of human retinal detachment reveals both inflammatory response and photoreceptor death // PLoS One. 2011. Vol. 6. № 12. P. 1-13.

9. Gronert K. Resolution, the grail for healthy ocular inflammation // Exp. Eye Res. 2010. Vol. 91. № 4. P. 478-485.

10. Kon C. H., Asaria R. H., Occleston N. L. et al. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study // Br. J. Ophthalmol. 2000. Vol. 84. № 5. P. 506-511.

11. Langenbach R., Morham S. G., Tiano H. F. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration // Cell. 1995. Vol. 83. № 3. P. 483-492.

12. Latendresse J. R., Warbrittion A. R., Jonassen H., Creasy D. M. Fixation of testes and eyes using a modified Davidson’s fluid: comparison with Bouin’s fluid and conventional Davidson’s fluid // Toxicol. Pathol. 2002. Vol. 30. № 4. P. 524-533.

13. Matsumura T., Yamanaka T., Hashizume S. et al. Tissue dispersion, cell harvest and fluid suspension culture by the use of bacterial neutral protease // Jpn J Exp Med. 1975. Vol. 45. № 5. P. 377-382.

14. Morham S. G., Langenbach R., Loftin C. D. et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse // Cell. 1995. Vol. 83. № 3. P. 473-482.

15. Nakazawa T., Matsubara A., Noda K. et al. Characterization of cytokine responses to retinal detachment in rats // Mol. Vis. 2006. Vol. 12. P. 867-878.

16. Nishijima K., Ng Y.-S., Zhong L. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury // Am. J. Pathol. 2007. Vol. 171. № 1. P. 53-67.

17. Pastor J. Proliferative vitreoretinopathy: an overview // Surv. Ophthalmol. 1998. Vol. 43. № 1. P. 3-18.

18. Prasad Byrav D. S., Medhi B., Prakash A. et al. Lornoxicam: a Newer NSAID // Indian J. Phys. Med. Rehabil. 2009. Vol. 20. № 1. P. 27-31.

19. Radi Z. A. Comparative Pathophysiology and Toxicology of Cyclooxygenases. Hoboken, New Jersey: John Wiley & Sons, 2012. 332 p.

20. Ricker L., Kessels A. Prediction of proliferative vitreoretinopathy after retinal detachment surgery: potential of biomarker profiling // Am. J. Ophthalmol. Elsevier Inc., 2012. Vol. 154. № 2. P. 347-354.

21. Roldan-Pallares M., Musa A. S., Bravo-Llatas C., Fernandez-Durango R. Preoperative duration of retinal detachment and subretinal immunoreactive endothelin-1: repercussion on logarithmic visual acuity // Graefes Arch Clin Exp Ophthalmol. 2010. Vol. 248. № 1. P. 21-30.

22. Silva D. J., Kwan A., Bunce C., Bainbridge J. Predicting visual outcome following retinectomy for retinal detachment // Br. J. Ophthalmol. 2008. Vol. 92. P. 954-958.

23. Walshe R., Esser P., Wiedemann P., Heimann K. Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction // Br. J. Ophthalmol. 1992. Vol. 76. № 9. P. 550-552.

24. Yang L. Preventing Retinal Detachment-Associated Photoreceptor Cell Loss in Bax-Deficient Mice // Invest. Ophthalmol. Vis. Sci. 2004. Vol. 45. № 2. P. 648-654.